A Phase I Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of opemalirsen (AZD2373)

Trial Identifier:	D6800C00006
Sponsor:	AstraZeneca
Start Date:	August 2025
Primary Completion Date:	December 2025
Study Completion Date:	December 2025
Condition:	Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, FL	Miami, FL, US, 33172
US, FL	Orlando, FL, US, 32808

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.